QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study

Key Takeaways QURE stock soared 247.7% after AMT-130 met primary and secondary endpoints in Huntington's disease study.High-dose AMT-130 slowed disease progression by 75% on cUHDRS and 60% on TFC at 36 months.AMT-130 showed dose-dependent benefits on motor and cognitive function with a manageable safety profile.Shares of uniQure N.V. (QURE) skyrocketed 247.7% on Wednesday after the company reported meeting key goals in the pivotal early to mid-stage study of its investigational gene therapy, AMT-130, for th ...